Redsense Medical’s partner Spindial remains winner of procurement contract in Italy after the appeal process
Redsense Medical AB (publ) announces that the result of the public procurement in Italy, where its partner Spindial was declared as one of the winners, are now final after a judicial appeal process. The parties will now sign the final agreement. The first order based on the contract is expected during the first quarter of 2018.
"It is encouraging that the result of the procurement has been declared final, and we look forward to delivering dialysis care with market leading patient safety in collaboration with our partners and Italian health care providers. I would also like to thank our Italian distributor Spindial for their hard work and professionalism during the procurement process," says Redsense Medical's CEO Patrik Byhmer.
"Spindial is proud to be able to present an unparalleled level of safety as a new standard of care to Italian dialysis clinics with the abilities of the Nikkiso and Redsense technologies,” says Ugo Grondelli, CEO of the Spindial group.
The procurement contract covers more than 3 million hemodialysis treatments during 5 years in Italy. Redsense Medical’s business partner Spindial was declared as one of the winners in September 2017. Their offer, including Redsense and Nikkiso products, was declared as one the top bids due to its high-quality offering.
For more information, please contact
Patrik Byhmer, CEO Redsense Medical AB (publ)
Telephone: +46 (0) 35 - 10 60 30
Email: patrik.byhmer@redsensemedical.com
Website: www.redsensemedical.com
About Redsense Medical
Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense system, a medical technology product used for monitoring and alarm in the case of blood leakage in connection with hemodialysis. Redsense solves one of the most serious remaining safety problems within hemodialysis – to quickly detect venous needle dislodgement and catheter leakage and minimizing blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. The company has also developed an internationally standardized direct connection enabling compatible dialysis machines to stop the blood flow automatically when blood leakage occurs. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.
This information is such information that Redsense Medical AB (publ) is obligated to publish in compliance with the EU market abuse regulation. This information was provided, through the above contact, for publication on the 20th of December 2017.